Sumary of Moderna says coronavirus vaccine protection declines, makes case for booster:
- New data from Moderna Inc’s large COVID-19 vaccine trial shows that the protection it offers declines over time, supporting the case for booster doses, the company said in a news release on Wednesday.
- Several recent studies have suggested that its vaccine may have an edge over a similar shot from Pfizer Inc and German partner BioNTech SE in terms of maintaining efficacy over time.
- Both vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.
- The analysis released on Wednesday, however, showed a chink in the Moderna shot’s armor over time, with higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago.
- Briefing documents from the FDA’s analysis of Pfizer’s booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning.
- Previous data on Moderna’s shot had shown lasting protection, making the case for boosters more challenging.
- In the new analysis, Moderna compared the vaccine’s performance in more than 14,000 volunteers vaccinated between July and October of 2020 to some 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2022 following its US emergency use authorization.
- They identified 88 COVID-19 cases among those who got the two shots more recently, compared with 162 cases among those vaccinated last year.